Customized Services for Cell Therapies
Custom Antibody & Nanobody Services
Cytoart specializes in providing solutions across every stage of cell therapy development. Since 2018, we have established a leadership position in providing transmembrane protein antibodies. Our mission is to accelerate the R&D, and enhance the clinical monitoring of CAR-T and other advanced cell therapies.
Fast Development Platform
Leveraging 8 years of antibody expertise, Cytoart establishes a fast (20weeks) antibody development platform to jumpstart and streamline your CAR development. We offer multiple animal platforms and bioscreening methods to meet your specific requirements.
VHH--CAR Design
Heavy-chain antibodies have the advantages of low immunogenicity and easy to engineer, so they are used as antigen-recognition ligand. (Ready for Test: CD19, CD20, BCMA)
VHH--T Cell Targeting
VHHs can be modified for in vivo CAR delivery vectors, enabling specific recognition and precise targeting of T cells. (Ready for Test: CD5, CD7, CD8)
PK/PD Studies
Anti-ID antibodies can specifically recognize the epitope of CAR, assisting the precision monitoring of cell therapy.
Immunogenicity Assessment
We provide rapid delivery of ADA detection tools including polyclonal antibodies, monoclonal antibodies, and tool cells.